CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 255 enrolled
Drug / intervention
loratadine +3 moredrug
Likely dose
loratadine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01469234
NCT01469234Phase 4Completed
CompareCT.gov

A Double-Blind, Parallel, Randomized, Placebo Controlled Trial to Evaluate Onset of Action of Loratadine and Fexofenadine in Subjects With Seasonal Allergic Rhinitis in a Pollen Challenge Chamber

Bayer·interventional·Posted Nov 10, 2011·Updated Mar 11, 2015

In Brief

A Phase 4 clinical trial evaluating loratadine, fexofenadine, and 2 other interventions for Rhinitis. Completed, enrolled 255 participants.

Detailed Summary

The purpose of this study is to determine the onset of action of two commercially available over-the-counter antihistamines (Loratadine and Fexofenadine) in a model of seasonal allergic rhinitis (SAR). Participants undergo sensitization exposures to Mountain Cedar (juniperus ashei) pollen in a Biogenics Research Chamber; those who demonstrate an adequate allergic response determined by the Major Symptom Complex (MSC) score will then receive drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 10, 2011
Enrollment StartOct 1, 2011
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.6 years ago

Interventions

loratadinedrug

loratadine, one 10 mg tablet, orally

fexofenadinedrug

fexofenadine, one 180 mg tablet, orally

placebo to loratadinedrug

one tablet, orally

placebo to fexofenadinedrug

one tablet, orally